Home

Märtyrer Weste Annehmen ac immune Switzerland Täglich Ei Im Ruhestand

AC Immune | LinkedIn
AC Immune | LinkedIn

AC Immune | LinkedIn
AC Immune | LinkedIn

13_08_28_Pfeifer.jpg – NCCR in Chemical Biology
13_08_28_Pfeifer.jpg – NCCR in Chemical Biology

SEC Filing | AC Immune SA
SEC Filing | AC Immune SA

AC Immune goes public - EPFL Innovation Park -
AC Immune goes public - EPFL Innovation Park -

AC Immune goes public - EPFL Innovation Park -
AC Immune goes public - EPFL Innovation Park -

AC Immune | LinkedIn
AC Immune | LinkedIn

The Alzheimer's debate may not seem positive, but AC Immune's CEO promises  it's been a breakthrough year | FierceBiotech
The Alzheimer's debate may not seem positive, but AC Immune's CEO promises it's been a breakthrough year | FierceBiotech

Swiss Consulate New York — AC Immune NASDAQ IPO
Swiss Consulate New York — AC Immune NASDAQ IPO

AC Immune (@AC_Immune_SA) / Twitter
AC Immune (@AC_Immune_SA) / Twitter

PDF) Discovery and preclinical characterization of [18F]PI-2620, a  next-generation tau PET tracer for the assessment of tau pathology in  Alzheimer's disease and other tauopathies
PDF) Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies

She Started It: Film Screening - Panel discussion and Apéro - EPFL
She Started It: Film Screening - Panel discussion and Apéro - EPFL

AC Immune | Image gallery
AC Immune | Image gallery

AC Immune goes public - EPFL Innovation Park -
AC Immune goes public - EPFL Innovation Park -

AC Immune - Crunchbase Company Profile & Funding
AC Immune - Crunchbase Company Profile & Funding

Sparknews - Founded in 2003, AC Immune biopharmaceutical company is  developing innovative therapeutics to confront one of the biggest health  challenges of our day: Alzheimer's disease. Andrea Pfeifer, the CEO, has  firsthand
Sparknews - Founded in 2003, AC Immune biopharmaceutical company is developing innovative therapeutics to confront one of the biggest health challenges of our day: Alzheimer's disease. Andrea Pfeifer, the CEO, has firsthand

AC Immune - Crunchbase Company Profile & Funding
AC Immune - Crunchbase Company Profile & Funding

Affiris – The Science of Parkinson's
Affiris – The Science of Parkinson's

EX-99.1 2 dp115375_ex9901.htm EXHIBIT 99.1 Exhibit
EX-99.1 2 dp115375_ex9901.htm EXHIBIT 99.1 Exhibit

AC Immune – Swiss Biotech
AC Immune – Swiss Biotech

AC Immune Shares Rise 19% as Firm Advances Alzheimers Vaccine in Phase  1b/2a Trial
AC Immune Shares Rise 19% as Firm Advances Alzheimers Vaccine in Phase 1b/2a Trial

AC Immune picks up Phase 2-ready drug for Parkinson's in $58M deal with  Affiris - MedCity News
AC Immune picks up Phase 2-ready drug for Parkinson's in $58M deal with Affiris - MedCity News

▷ Ac Immune SA, Lausanne | Cylex®
▷ Ac Immune SA, Lausanne | Cylex®

AC Immune – Swiss Biotech
AC Immune – Swiss Biotech

AC Immune (@AC_Immune_SA) / Twitter
AC Immune (@AC_Immune_SA) / Twitter

Investorideas.com - AC Immune Reports 'Positive Interim Results' from Novel  Phase 1b/2a Alzheimer's Vaccine Trial
Investorideas.com - AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial

New Vaccine Formulation Shows Promise for Alzheimer's Target | BioSpace
New Vaccine Formulation Shows Promise for Alzheimer's Target | BioSpace